ストックスクリーナーアプリを入手
62.90
0.11%
-0.08
アフターアワーズ：
61.88
-1.02
-1.62%
前日終値:
$62.98
開ける：
$61.875
24時間の取引高:
507.12K
Relative Volume:
0.36
時価総額：
$4.44B
収益：
-
当期純損益:
$-100.44M
株価収益率:
-28.33
EPS:
-2.22
ネットキャッシュフロー:
$-105.32M
1週間 パフォーマンス:
-6.27%
1か月 パフォーマンス:
-29.98%
6か月 パフォーマンス:
+213.30%
1年 パフォーマンス:
+164.88%
1日の値動き範囲:
$61.51
$64.37
1週間の範囲:
$61.51
$69.00
52週間の値動き範囲:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(650) 457-1978
住所
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
62.90 | 4.45B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.76 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.65 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-02 | 開始されました | Citigroup | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position - AOL.com
Private Capital Advisors Inc. Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
How Structure Therapeutics Inc. (GPCR) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 - TradingView
Structure Therapeutics Inc. (GPCR): Analyst Consensus Points To A 60% Upside Potential - DirectorsTalk Interviews
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake - AOL.com
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data - Finviz
Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Structure Therapeutics (GPCR) Projected to Post Earnings on Thursday - Defense World
Structure Therapeutics surges on phase 2 data for GLP-1 pill aleniglipron - MSN
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? - TradingView
Readystate Asset Management LP Increases Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Short Interest Down 17.8% in January - MarketBeat
(GPCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FY2030 Earnings Forecast for GPCR Issued By HC Wainwright - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), CSL (CMXHF) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Federated Hermes Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Entera Bio (ENTX) - The Globe and Mail
Assessing Structure Therapeutics (GPCR) Valuation As Oral Obesity Drug GSBR-1290 Advances In Phase 2 - Sahm
Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics’ Oral Obesity Drug Enters Phase 2 As Investor Focus Grows - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Down 10.7%Here's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE) - The Globe and Mail
UPDATE 3-Novo Nordisk warns on profits and sales amid Trump drug price crackdown - Sahm
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX) - The Globe and Mail
Responsive Playbooks and the GPCR Inflection - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Viking Therapeutics (VKTX) - The Globe and Mail
CCG Wealth Management LLC Sells 140,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Genentech Licensing Deal and Guggenheim Reaffirmation Could Be A Game Changer For Structure Therapeutics (GPCR) - Sahm
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Raised to "Strong-Buy" at The Goldman Sachs Group - MarketBeat
Understanding the Setup: (GPCR) and Scalable Risk - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Assessing Structure Therapeutics (GPCR) Valuation After Genentech Deal And Growing Obesity Pipeline Confidence - Sahm
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC
Goldman Sachs Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $102 - 富途资讯
Why Structure Therapeutics Stock Is Breaking Out Now - TipRanks
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7% - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
SG Americas Securities LLC Has $1.11 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR) and Penumbra (PEN) - The Globe and Mail
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
2.69%
大文字化:
|
ボリューム (24 時間):